Therapeutic effects of peroxisome proliferator-activated receptor alpha agonist on combat-induced proliferative vitreoretinopath

The Defense Health Agency (DHA) awarded Metis Foundation a $267,544 project grant effective September 1, 2025, through August 31, 2028, under the Military Medical Research and Development program (CFDA 12.420). The award funds research investigating the therapeutic effects of peroxisome proliferator-activated receptor alpha agonists on combat-induced proliferative vitreoretinopathy, a vision-threatening condition affecting military personnel. As a non-profit medical research organization based in San Antonio, Texas, Metis Foundation will provide comprehensive research coordination, scientific support, and biomedical research services to advance healthcare solutions for service members and veterans addressing this critical military health priority.

The project represents a hypothesis-driven research initiative consistent with the DHA's focus on transforming healthcare for military personnel through innovative medical solutions. Under the Military Medical Research and Development program's two-tier competitive review process, the award was selected based on technical merit and military relevance. Over the three-year performance period, Metis Foundation will conduct advanced biomedical research activities, including therapeutic development and translational research outcomes, leveraging their established expertise in supporting principal investigators and coordinating complex medical research initiatives for the defense medical community.